Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth Disease

Charcot–Marie–Tooth disease (CMT) is one of the most common inherited neuropathies and is a genetically and clinically heterogeneous disorder with variable inheritance modes. As several molecules have been reported to have therapeutic effects on CMT, depending on the underlying genetic causes, exact...

Full description

Saved in:
Bibliographic Details
Published inHuman mutation Vol. 33; no. 11; pp. 1610 - 1615
Main Authors Choi, Byung-Ok, Koo, Soo Kyung, Park, Mi-Hyun, Rhee, Hwanseok, Yang, Song-Ju, Choi, Kyoung-Gyu, Jung, Sung-Chul, Kim, Han Su, Hyun, Young Se, Nakhro, Khriezhanuo, Lee, Hye Jin, Woo, Hae-Mi, Chung, Ki Wha
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2012
Hindawi Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Charcot–Marie–Tooth disease (CMT) is one of the most common inherited neuropathies and is a genetically and clinically heterogeneous disorder with variable inheritance modes. As several molecules have been reported to have therapeutic effects on CMT, depending on the underlying genetic causes, exact genetic diagnostics have become very important for executing personalized therapy. Whole‐exome sequencing has recently been introduced as an available method to identify rare or novel genetic defects from genetic disorders. Particularly, CMT is a model disease to apply exome sequencing because more than 50 genes (loci) are involved in its development with weak genotype–phenotype correlation. This study performed the exome sequencing in 25 unrelated CMT patients who revealed neither 17p12 duplication/deletion nor several major CMT genes. This study identified eight causative heterozygous mutations (32%). This detection rate seems rather high because each sample was tested before the study for major genetic causes. Therefore, this study suggests that the exome sequencing can be a highly exact, rapid, and economical molecular diagnostic tool for CMT patients who are tested for major genetic causes. Hum Mutat 33:1610–1615, 2012. © 2012 Wiley Periodicals, Inc.
Bibliography:istex:4F94EC65532715567EBAF427BC6E94B6087BB005
Communicated by Christine Van Broeckhoven
National Project for Personalized Genomic Medicine (A111218-GM07) (PGM21 Project, A111218), Ministry for Health and Welfare, Korea
ArticleID:HUMU22143
ark:/67375/WNG-PBL73T1P-7
Both authors have equally contributed to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1059-7794
1098-1004
DOI:10.1002/humu.22143